• 35 sites active and enrolling in pivotal Phase 3 study of Bria-IMT™ combination with immune check point inhibitor in metastatic breast cancer (MBC)
  • Primary endpoint is overall survival (OS) with Bria-IMT™ regimen plus Check Point Inhibitor (CPI) vs treatment of physician's choice
  • Interim data analysis planned at 144 events (deaths) could provide full approval and marketing authorization
  • Pivotal Phase 3 study patient enrollment completion is expected in mid-2025
  • No serious adverse events related to Bria-IMT™ have been reported to date

Register to unlock this article

Register to read this story and more for free.

Signing up for an account helps us improve your browsing experience.

Continue

OR

See our subscription options.

Already have an account? Log in here